Active, Not Recruiting
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
NCT06308822
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States